Skip to Main Content
Contribute Try STAT+ Today

Top of the morning to you, and a fine one it is. Sunny skies and nippy winds are enveloping the Pharmalot campus, where the official mascot is itching to stroll through town and the sounds of the street are wafting through our windows. Meanwhile, we are as busy as ever, compiling a to-do list as we prepare for another busy day. Of course, this requires a few minutes in the cafeteria to brew cups of stimulation. Our choice today, for those tracking our addiction, is … blueberry. Meanwhile, please enjoy a few items of interest we have assembled for you. As always, we hope you conquer the world and, once again, please do keep us in mind if you hear anything saucy….

GlaxoSmithKline (GSK) and Vir Biotechnology (VIR) reported their Covid-19 antibody treatment retained effectiveness against the Omicron variant in laboratory studies, even as early data suggest that similar treatments work less well against the highly mutated strain, The Wall Street Journal tells us. The results provide hope that at least one monoclonal antibody therapy — a form of treatment that has proven useful in blunting severe disease — will remain effective against Omicron, which has been detected in dozens of countries since it was identified by scientists in South Africa two weeks ago.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment